Back to Results
First PageMeta Content
Immunosuppressants / Carfilzomib / Epoxides / Morpholines / Bortezomib / Proteasome inhibitor / Lenalidomide / Multiple myeloma / Onyx Pharmaceuticals / Chemistry / Medicine / Organic chemistry


NDA[removed]Carfilzomib (Kyprolis™) June 20, 2012 Oncologic Drugs Advisory Committee Thomas Herndon, M.D.
Add to Reading List

Open Document

File Size: 148,84 KB

Share Result on Facebook

Company

Onyx Pharmaceuticals / Application Applicant Onyx Pharmaceuticals / /

Event

FDA Phase / /

MedicalCondition

Multiple Myeloma / disease / relapsed disease / refractory multiple myeloma / /

Organization

FDA / Oncologic Drugs Advisory Committee / /

Person

Haleh Saber / Christine Garnett / Todd Palmby / Jeffrey Bray / Julie Bullock Christine / Thomas Herndon / Josephine Jee / Janice Brown / Nicole Gormley Albert Deisseroth / Koti Mark Rothmann / Jessica Hawes / Karen Bengtson Janet Jamison / Angelica Dorantes / William Adams / Bryan Riley / John Metcalfe / Anthony Orencia Susan / /

Position

Medical Officer / Reviewer Team Leader / Leibenhaut Project Manager / /

Product

Orencia / prednisone / Cyclophosphamide / Kyprolis™ / MM Regular Alkylating Agent / /

Technology

transplantation / /

SocialTag